Breast implant‑associated anaplastic large‑cell lymphoma and the role of brentuximab vedotin (SGN‑35) therapy: A case report and review of the literature

Jacobsen E: Anaplastic large-cell lymphoma, T-/null-cell type. Oncologist. 11:831–840. 2006. View Article : Google Scholar : PubMed/NCBI

Keech JA Jr and Creech BJ: Anaplastic T-cell lymphoma in proximity to a saline-filled breast implant. Plast Reconstr Surg. 100:554–555. 1997. View Article : Google Scholar : PubMed/NCBI

FDA: Anaplastic large cell lymphoma (ALCL) in women with breast implants: Preliminary FDA findings and analyses. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm239996.htmJune 7–2016.

Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S, Weisenburger DD, Liu J, Morgan EA, Kanagal-Shamanna R, et al: Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol. 34:160–168. 2016. View Article : Google Scholar : PubMed/NCBI

Miranda RN, Aladily TN, Prince HM, Kanagal-Shamanna R, de Jong D, Fayad LE, Amin MB, Haideri N, Bhagat G, Brooks GS, et al: Breast implant-associated anaplastic large-cell lymphoma: Long-term follow-up of 60 patients. J Clin Oncol. 32:114–120. 2014. View Article : Google Scholar : PubMed/NCBI

Adrada BE, Miranda RN, Clemens M, et al: Breast implant-associated anaplastic large cell lymphoma: Analysis of imaging studies in 44 patients reveals need for systematic assessment of mass versus no mass to improve diagnostic accuracy. Plast Reconstr Surg. 4:134: S95–S96. 2014.

Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, Matous J, Ramchandren R, Fanale M, Connors JM, et al: Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: Results of a phase II study. J Clin Oncol. 30:2190–2196. 2012. View Article : Google Scholar : PubMed/NCBI

Zimmerman A, Locke FL, Emole J, Rosa M, Horna P, Hoover S and Dayicioglu D: Recurrent systemic anaplastic lymphoma kinase-negative anaplastic large cell lymphoma presenting as a breast implant-associated lesion. Cancer Control. 22:369–373. 2015.PubMed/NCBI

O'Connor OA; Columbia University, : BBrentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) (SGN+Benda). https://clinicaltrials.gov/ct2/show/NCT01657331June 7–2016.

Seattle Genetics, Inc., . ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas (ECHELON-2). https://clinicaltrials.gov/ct2/show/NCT01777152June 7–2016.

Seattle Genetics, Inc, . Brentuximab Vedotin+Rituximab as Frontline Therapy for Pts w/CD30+ and/or EBV+Lymphomas. https://clinicaltrials.gov/ct2/show/NCT01805037June 7–2016.

National Cancer Institute, . Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II–IV Anaplastic Large Cell Lymphoma. https://clinicaltrials.gov/ct2/show/NCT01979536June 7–2016.

Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Huebner D, et al: Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: Results of a phase I study. J Clin Oncol. 32:3137–3143. 2014. View Article : Google Scholar : PubMed/NCBI

Ogura M, Tobinai K, Hatake K, Ishizawa K, Uike N, Uchida T, Suzuki T, Aoki T, Watanabe T, Maruyama D, et al: Phase I/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma. Cancer Sci. 105:840–846. 2014. View Article : Google Scholar : PubMed/NCBI

Bartlett NL, Chen R, Fanale MA, Brice P, Gopal A, Smith SE, Advani R, Matous JV, Ramchandren R, Rosenblatt JD, et al: Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies. J Hematol Oncol. 7:242014. View Article : Google Scholar : PubMed/NCBI